CEND-1 Cyclic Peptide Compositions for Deep Solid-Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-cancer drugs have limited efficacy for solid tumors due to their inability to penetrate beyond 3-5 cell diameters from blood vessels, especially in dense extracellular matrix stroma, leading to ineffective drug concentration in tumor areas.
Innovation Solution
Combining a novel iRGD-analog peptide, CEND-1, with chemotherapeutics to enhance tumor penetration and efficacy by modulating the tumor microenvironment, allowing deeper drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If conventional chemotherapeutics are administered, then systemic treatment is achieved, but tumor penetration is limited to 3-5 cell diameters from blood vessels
Solution Approach 1:
The patent employs a dual-functional peptide conjugate system where the iRGD peptide acts as an intermediary to facilitate deep tumor penetration. The peptide contains an RGD motif that binds to integrins on tumor vessels and a CendR motif that binds to neuropilin-1, creating a mediated transport pathway that enables chemotherapeutics to penetrate beyond the typical 3-5 cell diameter limitation into the dense stromal regions of solid tumors.
Solution Approach 2:
The invention creates a composite therapeutic agent by conjugating the iRGD peptide (containing both RGD and CendR motifs) with chemotherapeutic drugs. This composite structure combines the tumor-penetration capabilities of the peptide with the cytotoxic activity of the drug, enabling the drug to reach and exert its effect in previously inaccessible tumor regions.
2Reliability
If anti-cancer drugs are administered at high concentrations, then therapeutic efficacy is improved, but toxicity increases
Solution Approach 1:
The patent applies the local quality principle by enabling the chemotherapeutic to achieve high local concentration specifically within the tumor tissue through the iRGD-mediated penetration mechanism, while maintaining lower systemic concentrations. The peptide conjugate selectively delivers the drug to the tumor microenvironment, creating a localized high-concentration effect that improves therapeutic efficacy without proportionally increasing systemic toxicity.
3Reliability
If chemotherapy is administered to treat solid tumors, then cancer cells are targeted, but dense extracellular matrix stroma acts as a physical barrier
Solution Approach 1:
The iRGD peptide serves as a mediator that navigates through the dense extracellular matrix stroma to deliver the chemotherapeutic to cancer cells. The dual-motif structure (RGD and CendR) enables the peptide to interact with specific receptors (integrins and neuropilin-1) that are present in the tumor microenvironment, creating a facilitated transport pathway through the stromal barrier that conventional drugs cannot traverse.
Data Source
AI summary
Provided herein are novel cyclic peptides, their synthetic process, compositions, properties including stability and pharmacokinetic profiles, and applications for treating solid tumor cancers.